Amyris Inc (NASDAQ:AMRS) dropped 6% on Wednesday . The stock traded as low as $7.81 and last traded at $7.82. Approximately 959,200 shares changed hands during mid-day trading, an increase of 30% from the average daily volume of 735,267 shares. The stock had previously closed at $8.32.

AMRS has been the topic of several analyst reports. HC Wainwright set a $15.00 target price on shares of Amyris and gave the stock a “buy” rating in a report on Thursday, August 30th. BidaskClub raised shares of Amyris from a “hold” rating to a “buy” rating in a report on Wednesday, August 15th. ValuEngine raised shares of Amyris from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Zacks Investment Research lowered shares of Amyris from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. Finally, B. Riley set a $10.00 target price on shares of Amyris and gave the stock a “buy” rating in a report on Monday, September 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $9.13.

The company has a debt-to-equity ratio of -0.24, a quick ratio of 0.38 and a current ratio of 0.42. The firm has a market capitalization of $403.45 million, a price-to-earnings ratio of -2.70 and a beta of 0.20.

Amyris (NASDAQ:AMRS) last posted its earnings results on Monday, August 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). The firm had revenue of $24.81 million for the quarter, compared to analyst estimates of $37.52 million. During the same quarter last year, the firm posted ($1.32) earnings per share. The business’s revenue was down 3.4% compared to the same quarter last year. equities analysts predict that Amyris Inc will post -1.41 earnings per share for the current year.

In related news, Director Patrick Y. Yang acquired 10,000 shares of the firm’s stock in a transaction on Thursday, August 9th. The shares were purchased at an average price of $7.71 per share, with a total value of $77,100.00. Following the acquisition, the director now directly owns 36,932 shares in the company, valued at $284,745.72. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Eduardo Alvarez acquired 11,877 shares of the firm’s stock in a transaction on Wednesday, September 5th. The shares were bought at an average cost of $8.45 per share, for a total transaction of $100,360.65. Following the acquisition, the chief operating officer now owns 331,877 shares in the company, valued at $2,804,360.65. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 50,877 shares of company stock worth $393,161 and sold 8,824,625 shares worth $54,897,886. 21.80% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd bought a new stake in Amyris during the 1st quarter worth about $110,000. Rhumbline Advisers bought a new stake in Amyris during the 2nd quarter worth about $147,000. Renaissance Technologies LLC bought a new stake in Amyris during the 2nd quarter worth about $167,000. Element Capital Management LLC bought a new stake in Amyris during the 1st quarter worth about $227,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in Amyris during the 2nd quarter worth about $292,000. 27.90% of the stock is currently owned by hedge funds and other institutional investors.

Amyris Company Profile (NASDAQ:AMRS)

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

See Also: How is an ETF different from a mutual fund?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.